Related references
Note: Only part of the references are listed.Newborn screening for Fabry disease in the western region of Japan
Takaaki Sawada et al.
MOLECULAR GENETICS AND METABOLISM REPORTS (2020)
Safety and effectiveness of enzyme replacement therapy with agalsidase alfa in patients with Fabry disease: Post-marketing surveillance in Japan
Hiroaki Sasa et al.
MOLECULAR GENETICS AND METABOLISM (2019)
A Novel α-Galactosidase A Splicing Mutation Predisposes to Fabry Disease
Ping Li et al.
FRONTIERS IN GENETICS (2019)
Mutation spectrum of α-Galactosidase gene in Japanese patients with Fabry disease
Masahisa Kobayashi et al.
JOURNAL OF HUMAN GENETICS (2019)
High-risk screening for Anderson-Fabry disease in patients with cardiac, renal, or neurological manifestations
Naoki Nakagawa et al.
JOURNAL OF HUMAN GENETICS (2019)
Genetic analysis of 1051 Chinese families with Duchenne/Becker Muscular Dystrophy
Xiangdong Kong et al.
BMC MEDICAL GENETICS (2019)
Improvement in the sensitivity of newborn screening for Fabry disease among females through the use of a high-throughput and cost-effective method, DNA mass spectrometry
Yung-Hsiu Lu et al.
JOURNAL OF HUMAN GENETICS (2018)
Fabry Disease: prevalence of affected males and heterozygotes with pathogenic GLA mutations identified by screening renal, cardiac and stroke clinics, 1995-2017
Dana Doheny et al.
JOURNAL OF MEDICAL GENETICS (2018)
Functional and biological studies of α-galactosidase A variants with uncertain significance from newborn screening in Taiwan
Hsuan-Chieh Liao et al.
MOLECULAR GENETICS AND METABOLISM (2018)
Mutations in the GLA Gene and LysoGb3: Is It Really Anderson-Fabry Disease?
Giovanni Duro et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Fabry disease in a Japanese population-molecular and biochemical characteristics
Hitoshi Sakuraba et al.
MOLECULAR GENETICS AND METABOLISM REPORTS (2018)
Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study
Derralynn A. Hughes et al.
JOURNAL OF MEDICAL GENETICS (2017)
Fabry disease in children: a federal screening programme in Russia
Leyla Seymurovna Namazova-Baranova et al.
EUROPEAN JOURNAL OF PEDIATRICS (2017)
Newborn Screening for Lysosomal Storage Disorders in Illinois: The Initial 15-Month Experience
Barbara K. Burton et al.
JOURNAL OF PEDIATRICS (2017)
Enzyme replacement therapy in a patient of heterozygous Fabry disease: clinical and pathological evaluations by repeat kidney biopsy and a successful pregnancy
Yoichi Iwafuchi et al.
CEN CASE REPORTS (2017)
Imbalanced Production of Reactive Oxygen Species and Mitochondrial Antioxidant SOD2 in Fabry Disease-Specific Human Induced Pluripotent Stem Cell-Differentiated Vascular Endothelial Cells
Wei-Lien Tseng et al.
CELL TRANSPLANTATION (2017)
ClinVar: public archive of interpretations of clinically relevant variants
Melissa J. Landrum et al.
NUCLEIC ACIDS RESEARCH (2016)
Case report of a 45-year old female Fabry disease patient carrying two alpha-galactosidase A gene mutation alleles
Daniel Oder et al.
BMC MEDICAL GENETICS (2016)
Pain in Fabry Disease: Practical Recommendations for Diagnosis and Treatment
Juan M. Politei et al.
CNS NEUROSCIENCE & THERAPEUTICS (2016)
Treatment of Fabry's Disease with the Pharmacologic Chaperone Migalastat
D. P. Germain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
De novo Diagnosis of Fabry Disease among Italian Adults with Acute Ischemic Stroke or Transient Ischemic Attack
Ilaria Romani et al.
JOURNAL OF STROKE & CEREBROVASCULAR DISEASES (2015)
De novo Diagnosis of Fabry Disease among Italian Adults with Acute Ischemic Stroke or Transient Ischemic Attack
Ilaria Romani et al.
JOURNAL OF STROKE & CEREBROVASCULAR DISEASES (2015)
Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: A Fabry Outcome Survey analysis
Michael Beck et al.
MOLECULAR GENETICS AND METABOLISM REPORTS (2015)
Uncertain diagnosis of Fabry disease: Consensus recommendation on diagnosis in adults with left ventricular hypertrophy and genetic variants of unknown significance
B. E. Smid et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2014)
Plasma mutant alpha-galactosidase A protein and globotriaosylsphingosine level in Fabry disease
Takahiro Tsukimura et al.
MOLECULAR GENETICS AND METABOLISM REPORTS (2014)
Fabry nephropathy: indications for screening and guidance for diagnosis and treatment by the European Renal Best Practice
Wim Terryn et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2013)
Identification of a Novel Mutation and Prevalence Study for Fabry Disease in Japanese Dialysis Patients
Tomoya Nishino et al.
RENAL FAILURE (2012)
Newborn Screening for Lysosomal Storage Disorders
Kimitoshi Nakamura et al.
AMERICAN JOURNAL OF MEDICAL GENETICS PART C-SEMINARS IN MEDICAL GENETICS (2011)
Fabry-database.org: database of the clinical phenotypes, genotypes and mutant α-galactosidase A structures in Fabry disease
Seiji Saito et al.
JOURNAL OF HUMAN GENETICS (2011)
Misdiagnosis in Fabry Disease
Cintia L. Marchesoni et al.
JOURNAL OF PEDIATRICS (2010)
Fabry disease: a review of current management strategies
A. Mehta et al.
QJM-AN INTERNATIONAL JOURNAL OF MEDICINE (2010)
Cardiac Microvascular Pathology in Fabry Disease Evaluation of Endomyocardial Biopsies Before and After Enzyme Replacement Therapy
Beth L. Thurberg et al.
CIRCULATION (2009)
Life expectancy and cause of death in males and females with Fabry disease: Findings from the Fabry Registry
Stephen Waldek et al.
GENETICS IN MEDICINE (2009)
Enzyme activity for determination of presence of Fabry disease in women results in 40% false-negative results
Gabor E. Linthorst et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2008)
Fabry disease: Baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry
C. M. Eng et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2007)
Clinical manifestations of Fabry disease in children: Data from the Fabry outcome survey
U Ramaswami et al.
ACTA PAEDIATRICA (2006)
Fabry disease: molecular studies in Italian patients and X inactivation analysis in manifesting carriers
A Morrone et al.
JOURNAL OF MEDICAL GENETICS (2003)
Fabry disease: D313Y is an alpha-galactosidase A sequence variant that causes pseudodeficient activity in plasma
R Froissart et al.
MOLECULAR GENETICS AND METABOLISM (2003)
Alternative splicing in the α-galactosidase A gene:: Increased exon inclusion results in the Fabry cardiac phenotype
S Ishii et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2002)
Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females
KD MacDermot et al.
JOURNAL OF MEDICAL GENETICS (2001)
Share Paper
